Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Gene therapy injected into tumors slowed cancer growth in mice

☕ Includes a question for the family ↓

Gene and cell therapiesPart of a story we are following · 4 articles · See every update
Two people walk side by side along the shore of a lake.
Two people walk side by side along the shore of a lake.Photo: bluesbby from Mountain View, USA / Wikimedia Commons, CC BY 2.0

If you follow cancer news, here is an early, hopeful lab result to keep in the back of your mind. A gene therapy shot placed right inside a tumor slowed its growth in mice. It has not been tested in people, so it is not a treatment you can ask for.

In lab-grown cells and in mice, researchers used a gene-editing tool delivered straight into tumors to switch off a protein called CD47. Tumors in the treated mice grew more slowly, and more immune cells showed up inside them. The study summary does not say how many mice were used.

How the study worked

This was an early lab study, done in cancer cells grown in dishes and in mice, with no people involved. The team built a compact gene-editing system small enough to fit inside a single AAV, a tiny delivery vehicle with very little room for cargo, and injected it directly into tumors. The work was published on November 20, 2026 in Molecular Therapy. Results in mice often do not carry over to people, and this approach has not been approved by the FDA for any use.

What did the researchers find?

The team tested several compact gene editors and picked one that switched off the mouse version of CD47 in more than 60% of cells (the abstract reports it as >60%). That was about as good as a larger editor, and it also looked precise.

Turning off CD47 had two effects. In dishes, immune cells called macrophages swallowed up more cancer cells. In mice, tumors grew more slowly.

The team then built the full single-shot system and named it SOLO-CD47. It uses two guide signals at once to steer the editor to the right spot in the DNA. The researchers injected it right into tumors, and the tumors grew more slowly. The researchers saw no short-term changes in the blood counts they checked.

When they looked inside the treated tumors, they found more of two kinds of immune cells. One was a group of macrophage-related cells. The other was CD8+ T cells, a type of immune cell that can attack other cells.

The researchers also built a version aimed at the human gene. It switched off CD47 in more than 60% of cells across several human cancer cell lines. Those were cells grown in the lab, not tumors in people.

Why put the treatment inside the tumor?

Some cancer drugs that target CD47 are given through the bloodstream, so they travel through the whole body. The researchers point out that a local shot could reduce side effects that come with that. Keeping the gene editing inside the tumor is the idea behind this work.

The small size of the editor matters too. Common gene editors are too big to fit in a single AAV. This smaller one does fit, which makes a one-shot approach possible.

What you can do today

Nothing changes for you today. This is a proof-of-concept in mice and lab cells, and there is no version for people to take. The best use of this story is to know that researchers are testing ways to wake up the immune system inside a tumor, and to watch for news if it reaches studies in people.

For clinicians and researchers

Design: Preclinical study in mouse models and human cancer cell lines. Hypercompact CRISPR-Cas12f systems were benchmarked for CD47 editing, then delivered as a single AAV (SOLO-CD47) by intratumoral injection. Sample sizes and follow-up are not given in the abstract.

Main result: AsCas12f-HKRA achieved >60% mouse Cd47 editing, comparable to enAsCas12a-HF. Intratumoral SOLO-CD47 suppressed tumor growth without detectable short-term hematologic abnormalities, and human-targeting SOLO-CD47 achieved >60% CD47 editing across multiple human cancer cell lines.

Main limitation: Preclinical work in mice and cell lines; hematologic safety was assessed only in the short term, and the abstract reports no human tumor efficacy data.

Open question: Whether the human-targeting SOLO-CD47 suppresses tumors in vivo, and whether safety and off-target specificity hold over longer follow-up, remains to be tested.

Talk about it at home

Your body has tiny cleaner cells that gobble up things that do not belong, a bit like a helper who tidies a messy room. Some unhealthy cells wear a “do not eat me” sign, like a sticker on a lunchbox that says hands off. In mice, scientists used a tiny gene tool to peel that sticker off, and the cleaner cells showed up in greater numbers while the unhealthy growth slowed down.

Try it at home

Play cleanup detectives with toys: stick little paper notes that say skip me on some of them, then let someone with eyes closed tidy the room by feeling for toys without a note. Peel the notes off and try again, and talk about what changed.

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Gene therapy injected into tumors slowed cancer growth in mice. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/mongevity-tech/2026/11/gene-therapy-tumor-injection-mice-cd47/
Vancouver
Mongevity Desk. Gene therapy injected into tumors slowed cancer growth in mice [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/mongevity-tech/2026/11/gene-therapy-tumor-injection-mice-cd47/
APA
Mongevity Desk. (2026, November 21). Gene therapy injected into tumors slowed cancer growth in mice. Mongevity. https://mongevity.science/mongevity-tech/2026/11/gene-therapy-tumor-injection-mice-cd47/
For your website
<a href="https://mongevity.science/mongevity-tech/2026/11/gene-therapy-tumor-injection-mice-cd47/">Gene therapy injected into tumors slowed cancer growth in mice</a>

Free to share or quote with credit and a link.

Questions and answers

Has this gene therapy been tested in people?
No. It was tested in lab-grown cells and in mice. The human version only edited human cancer cells grown in dishes.
What is CD47?
CD47 is a protein found on cells. In this study, switching it off made immune cells called macrophages swallow more cancer cells in dishes, and tumors in mice grew more slowly.
What is an AAV?
It is a tiny delivery vehicle used in gene therapy to carry gene-editing tools into cells. It has little room for cargo, so the team used a very compact editor.
Is this treatment approved by the FDA?
No. It is an early experiment and has not been approved for any use.

Sources

  1. Mol Ther: SOLO-CD47: an all-in-one AAV strategy for localized CRISPR-Cas12f-mediated CD47 editing in cancer immunotherapy (PMID 43065199 · DOI 10.1016/j.ymthe.2026.11.030) · 2026-11-21

More on this story

Report an error